Denali Therapeutics (DNLI) Non-cash Items (2017 - 2018)

Name: Denali Therapeutics (DNLI) Non-cash Items (2017 - 2018) | Business Quant
Creator: Business Quant

Denali Therapeutics (DNLI) reported Non-cash Items of $95.8 million for Q1 2018, up 23.89% on a QoQ basis from $77.3 million in Q4 2017.

Denali Therapeutics (DNLI) has 2 years of Non-cash Items data on file, last reported at $95.8 million in Q1 2018.

Quarterly Non-cash Items changed N/A year-over-year to $95.8 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $95.8 million (changed N/A YoY) and the FY2017 annual result came in at $77.3 million, changed N/A from the prior year.
Non-cash Items climbed to $95.8 million in Q1 2018 per DNLI's latest filing, from $77.3 million in the prior quarter.
Across five years, Non-cash Items topped out at $95.8 million in Q1 2018 and bottomed at $77.3 million in Q4 2017.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Denali Therapeutics	3.82 Bn	3.82 Bn	-

Download Data 🔒